The phase 3 clinical trial Rituximab in the Study of Relapsed Chronic Lymphocytic Leukemia (REACH) included 457 patients, out of which 37 had del17p and 52 had TP53 mutations. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.